Operational targets 

Pipeline targets

Financial outlook 2018*

Strengthen commercial focus Progress development towards a self-sustained R&D pipeline Revenues of SEK 7,900-8,100 M (7,500-7,700)
Increase sales of Elocta and Alprolix in existing and new markets Begin SOBI003 first in human phase 1/2 study Gross margin of at least 70 per cent
Increase sales of Kineret in existing markets and in applications Complete enrolment into the ReITIrate study EBITA of SEK 2,800-3,000 (2,500-2,700)
Expand our commercial portfolio through new in-licensing, acquisitions or partnerships focused on Europe and North America. Phase 2 Gout (anakinra) key results for phase 3 decision  
  Expand R&D pipeline with new late-stage assets.  

* At current exchange rates as of 26 April 2018. The original outlook was published on 22 February 2018.